Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)
On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer
Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)